EPB154	Doravirine associated resistance mutations in antiretroviral therapy naïve and experienced HIV-1C infected people in Botswana	E-poster	ART in highly treatment-experienced persons
EPB155	The presence of minority HIV Drug resistance variants in the protease and Gag regions confers poor response to therapy among subtype A and D patients	E-poster	ART in highly treatment-experienced persons
EPB156	How clinical trials of combination antiretroviral therapy for adults with HIV capture health-related quality of life with patient-reported measures: a systematic review	E-poster	ART in highly treatment-experienced persons
EPB157	Comparison of virologic suppression rates among first- and second-line antiretroviral therapy patients at an urban clinic in Zimbabwe: a cohort study	E-poster	ART in highly treatment-experienced persons
EPB158	Low level of virologic failure and resistance in ART-experienced, integrase inhibitor-naïve participants receiving dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) combined regimens: 10-year follow-up in the SAILING Study	E-poster	ART in highly treatment-experienced persons
EPB159	Safety and efficacy of switching to BIC/FTC/TAF plus DOR in HIV-infected patients with multiclass-resistant virus	E-poster	ART in highly treatment-experienced persons
EPB160	Efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1: week 240 results of the Phase 3 BRIGHTE study	E-poster	ART in highly treatment-experienced persons
EPB161	Switching EFV/FTC/TDF to B/F/TAF or generic EFV/FTC/TDS in virologically suppressed adults with human immunodeficiency virus: a 96-week retrospective cohort	E-poster	Regimen simplification and switch studies
EPB162	Integrase resistance emergence with dolutegravir/lamivudinewith prior HIV-1 suppression	E-poster	Regimen simplification and switch studies
EPB163	Real-world HIV renal outcomes with TDF-to-TAF switch	E-poster	Regimen simplification and switch studies